86P Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study

A.R He,J.W Valle,C-K Lee,M Ikeda,P Potemski,C Morizane,J.E Cundom,D Tougeron,F Dayyani,N Rokutanda,J Xiong,G Cohen,D-Y Oh

doi:10.1016/j.annonc.2022.10.122

86P Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study

A.R He, J.W Valle + Show 11 more

Open Access

https://doi.org/10.1016/j.annonc.2022.10.122

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2022
License type: publisher-specific-oa

Affiliation: Georgetown University, University of Manchester, Yonsei University, National Cancer Center Hospital East, Medical University of Lodz, Centre Hospitalier Universitaire de Poitiers, University of California, Irvine, Seoul National University

#Primary Tumour Location #Advanced Biliary Tract Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

TOPAZ-1 (NCT03875235) is a double-blind, Phase 3 study of durvalumab (D) + gemcitabine and cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC). D + GemCis improved overall survival (OS) vs placebo (PBO) + GemCis, and is a potential new treatment option (Oh et al. NEJM Evid 2022; https://doi.org/10.1056/EVIDoa2200015). In BTC, primary tumour location may impact risk factors, prognoses and treatment response.

Full Text